Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 11Rituximab 9fludarabine phosphate 7fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Methotrexate 4Alemtuzumab 4Tacrolimus 3Prednisone 3Melphalan 3Cytogenetic Analysis 3Busulfan 3Vincristine 2Pentostatin 2Patient Reported Outcome Measures 2Mesna 2In Situ Hybridization, Fluorescence 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Doxorubicin 2Bendamustine Hydrochloride 2ruxolitinib 1plerixafor 1pegfilgrastim 1merphos 1liposomal amphotericin B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Lymphocytic, Chronic, B-Cell × NVP-BKM120 × Clear all
NCT02340780 2023-08-22

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Canadian Cancer Trials Group

Phase 2 Completed
14 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡